Early estimates of SARS-CoV-2 B.1.1.7 variant emergence in a university setting
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Recent identification of the highly transmissible novel SARS-CoV-2 variant in the United Kingdom (B.1.1.7) has raised concerns for renewed pandemic surges worldwide 1,2 . B.1.1.7 was first identified in the US on December 29, 2020 and may become dominant by March 2021 3 . However, the regional prevalence of B.1.1.7 is largely unknown because of limited molecular surveillance for SARS-CoV-2 4 . Quantitative PCR data from a surveillance testing program on a large university campus with roughly 30,000 students provides local situational awareness at a pivotal moment in the COVID-19 pandemic.
Article activity feed
-
SciScore for 10.1101/2021.03.05.21252541: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank…
SciScore for 10.1101/2021.03.05.21252541: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
